Exclusive Summary

• **Off-the-Shelf Potential**: Utilizing the iPSC-CARNK platform enables the development of true 'off-the-shelf' allogeneic therapies, overcoming the high cost and long manufacturing turnaround of autologous CAR-T.
• **Superior Safety Profile & Solid Tumor Efficacy**: Compared to CAR-T, NK cell therapies typically exhibit lower risks of CRS and neurotoxicity. Targeted at 'Advanced Cancers', UB496 aims to address the unmet needs in solid tumors.
• **Automated Manufacturing Barrier**: Supported by a world-class, fully automated cell production platform with full proprietary rights, ensuring batch-to-batch consistency (CMC advantage) and scalability.
• **De-risked via Clinical Data**: Currently in the IIT (Investigator-Initiated Trial) stage aiming for IND, offering preliminary clinical proof-of-concept data that significantly reduces development risks for potential partners.

Asset Materials

Contact Us for Full Materials